- Global Pharma News & Resources

Global Vectorized Antibodies for In Vivo Expression Market - by DNA and mRNA -

DUBLIN--(BUSINESS WIRE)--The "Vectorized Antibodies for In Vivo Expression by DNA and mRNA: A Landscape Analysis Of Stakeholders, Technologies, Targets, Business and Financing from an Industry Perspective" report has been added to's offering.

This report provides you with a landscape description and analysis of direct in vivo delivery of nucleic acid-encoded antibodies employing DNA and mRNA platform technologies from an industry perspective as of July 2021. In vivo gene-encoded antibody delivery is an elegant approach to address many of the limitations of conventional therapeutic antibodies. The three main approaches for antibody vectorization are:

  • Adenoassociated virus (AAV) vector for delivery of DNA: AAV DNA;
  • Synthetic plasmid DNA utilizing an electroporation device to enhance transfection efficiency after IM delivery: plasmid DNA;
  • mRNA formulated in lipid nanoparticles (LNP): LNP mRNA.

Companies Mentioned

  • 4D Molecular Therapeutics (4DMT)
  • AbbVie
  • Adverum Biotechnologies
  • AstraZeneca
  • BioNTech
  • Curevac
  • Eli Lilly
  • Ethris
  • Eyevensys
  • Generation Bio
  • Genmab
  • GlaxoSmithKline
  • Homology Medicines
  • Inovio Pharmaceuticals
  • Kernal Bio
  • Kernal Biologics
  • MeiraGTx
  • Merck
  • Moderna Therapeutics
  • Neurimmune
  • Regeneron Pharmaceuticals
  • Regenxbio
  • SmartPharm Therapeutics & Sorrento Therapeutics
  • University of Pennsylvania (U'Penn), Wilson Gene Therapy Program (GTP)
  • U'Penn
  • VectorY
  • Vir Biotechnology
  • Voyager Therapeutics
  • Vybion

The report brings you up-to-date with information about and analysis of

  • Approaches of in vivo expression of therapeutic antibodies;
  • Stakeholders in the field: technology and major pharmaceutical companies and investors;
  • Gene therapy technologies for antibody vectorization: DNA, mRNA;
  • Delivery technologies: adenoassociated virus (AAV) vector; electroporation; lipid nanoparticles (LNPs)
  • Targets and therapeutic indications selected for development of vectorized antibodies;
  • Preclinical and clinical experience with selected vectorized antibodies;
  • Financing situation of technology companies and key investors in the field
  • Partnering deals with financial terms;
  • Business strategy: indications, development path, technology partnering, investment case;
  • Major pharmaceutical companies: in-house technologies, R&D, collaborations.

Passive immunotherapy with conventional recombinant monoclonal antibodies has become a clinically and commercially extremely successful treatment modality. Breakthroughs in recombinant antibody technologies have resulted in the regulatory approval and commercialization of over 100 monoclonal antibodies (mAbs) to treat a variety of diseases. Sales of recombinant therapeutic antibodies in the year 2020 exceeded US$ 184 bln (+11% vs previous year).

However, there exist a number of limitations and challenges for passive immunotherapy. Manufacturing of recombinant antibodies requires large volumes, costly production and complex protein characterization. Delivery challenges must also be overcome as in vivo administration of mAb biologics often requires high doses (grams of mAb) to achieve therapeutic efficacy, frequently at a high cost. Bioprocess manufacturing and purification can be lengthy and costly. mAbs requiring higher doses need to be administered through slow intravenous (IV) infusions to limit infusion reactions. IV delivery frequently requires hours of clinical monitoring and may involve post-infusion monitoring for allergic or anaphylactic reactions, further increasing the medical personnel required and costs of administration. Subcutaneous (SC) delivery has advantages for lower dose antibody delivery. However, SC delivery is associated with pain related to injection volume and injection site reactions, and absorption is slow due to reliance on the lymphatic system for biodistribution.

Another limitation of recombinant antibodies is their relatively short half leading to the need for repeated administration in case of chronic therapy which can be inconvenient for local administration into the eye (e.g. intravitreal). The blood-brain barrier (BBB) is a special concern for recombinant antibody therapy. The BBB prevents antibody entry to the central nervous system (CNS). Furthermore, antibodies do not enter the intracellular proteome. Systemically administered recombinant antibodies also have a potential for unspecific or toxic off-target effects.

Antibody vectorization intends to overcome such limitations of conventional passive immunotherapy. Each of the three different approaches (AAV DNA, plasmid DNA and mRNA) for in vivo expression of antibodies has its specific profile of advantages and disadvantages.

This report evaluates the industry landscape of antibody vectorization with optimized technologies for direct in vivo delivery of synthetic nucleic acid-encoded antibodies. The report is based on the identification and description of 26 companies with activities in the field of in vivo expressed therapeutic antibodies

For each vectorized antibody technology company, a profile has been elaborated providing information about the company background/history, the financial situation, relevant technology, partnering deals and target & pipeline overview. Short profiles of the major pharmaceutical and antibody technology companies are combined in a separate paragraph. The company profiles are preceded by a chapter of stakeholder analysis.

Key Topics Covered:

1 Executive Summary

2 Introduction & Overview

3 Stakeholder Analysis

4 Profiles of Stakeholders in Vectorized Antibody Technologies

5 Analysis of Vectorized Antibody Technologies

6 Profiles of Vectorized Antibody Technologies

7 Analysis of Pipeline and Product Candidates for In Vivo Expression of Antibodies

8 Profiles of Vectorized Antibody Product Candidates

9 Business, Financing & Partnering

10 References

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 13-Jul-2021